News | December 17, 2010

Mammography Technology Highlighted at RSNA

December 17, 2010 – A new mammography technology that was displayed at RSNA 2010 is pending 510(k) approval by the U.S. Food and Drug Administration (FDA). The SenoBright Contrast Enhanced Spectral Mammography (CESM) technology is designed to let a physician image blood flow through angiography of the breast using a contrast agent and a dual energy acquisition technique.

Contrast agents can be used to highlight angiogenesis, the growth of small blood vessels potentially related to the presence of cancer. In addition to typical mammography images that show breast tissue density, CESM technology is designed to provide doctors with images of contrast uptake, which may indicate angiogenesis.

SenoBright uses X-rays at multiple energies to create two separate exposures. These resulting images specifically illuminate and highlight areas where there is contrast uptake and potentially angiogenesis.

"CESM presents images that look like mammography images with additional functional information. As the images are familiar, it can therefore be easily reviewed by surgeons and oncologists. Moreover in terms of workflow, a CESM exam takes from 5 to 10 minutes," said Clarisse Dromain, Gustave Roussy Cancer Institute, France.

As mammography mainly images tissue densities, SenoBright has been designed to produce an image that maps contrast uptake, adding the functional information to the conventional standard tissue density information of mammography. Doctors can highlight the proliferation of small blood vessels, potentially associated with cancerous tumor growth. Patients receive an intravenous injection of standard iodine contrast agent, and after two minutes undergo a five-minute digital mammography exam. CESM images are acquired in familiar mammography views so that that they can be correlated with standard results, facilitating interpretation by other specialists.

SenoBright is intended to allow for a procedure to be conducted by the same staff, using the same mammography equipment, potentially on the same day as the exam. This enables medical professionals to cut the critical time patients often have to wait from detection to diagnosis.

Digital mammography is considered a relevant means of breast cancer screening, delivering proven clinical outcomes. The sensitivity and specificity of images can, however, be affected by a range of factors. Dense breast tissue can overlap with lesions, which are not always visible on an X-ray, and radiologists’ interpretation of images can vary. Inconclusive digital mammography presents a range of challenges to healthcare professionals and patients. Ambiguity can result in diagnostic error.

CESM technology is intended to work as an upgrade to GE Healthcare’s Senographe DS and Senographe Essential digital mammography equipment.

SenoBright has not received the CE Mark and is not available for sale in the United States.

For more information: www.gehealthcare.com

Related Content

Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...
Novarad Debuts NovaMG-Pro Mammography Software at RSNA 2018
News | Mammography Reporting Software | November 25, 2018
Novarad Corp. announced new mammography software NovaMG-Pro, specifically for multimodality radiologists that read...
Volpara Solutions Showcases Latest VolparaEnterprise Software Tools at RSNA
News | Mammography | November 21, 2018
Volpara Solutions Inc. will showcase its latest artificial intelligence (AI) updates at the 104th Annual Radiological...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...